Format

Send to

Choose Destination
Br J Cancer. 2005 May 9;92(9):1599-610.

The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations.

Author information

1
Cancer Research UK Clinical Magnetic Resonance Research Group, Institute of Cancer Research, Royal Marsden Hospital, Sutton, Surrey, UK. martin.leach@icr.ac.uk

Abstract

Vascular and angiogenic processes provide an important target for novel cancer therapeutics. Dynamic contrast-enhanced magnetic resonance imaging is being used increasingly to noninvasively monitor the action of these therapeutics in early-stage clinical trials. This publication reports the outcome of a workshop that considered the methodology and design of magnetic resonance studies, recommending how this new tool might best be used.

PMID:
15870830
PMCID:
PMC2362033
DOI:
10.1038/sj.bjc.6602550
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center